Zaharadeen Jimoh

Mr. Zaharadeen Jimoh

University of Alberta
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
Nahla GomaaNahla Gomaa
Nahla Gomaa
ZJZaharadeen Jimoh
Zaharadeen Jimoh
SCSandra M Campbell
Sandra M Campbell
JZJulianna K. Zenke
Julianna K. Zenke
Agnieszka J. SzczepekAgnieszka J. Szczepek
Agnieszka J. Szczepek
The diagnostics of inner ear diseases are primarily functional, but there is a growing interest in inner ear biomarkers. The present scoping review aimed to elucidate gaps in the literature regarding the definition, classification system, and an overview of the potential uses of inner ear biomarkers. Relevant biomarkers were categorized, and their possible benefits were evaluated. The databases OVID Medline, EMBASE, EBSCO COINAHL, CA PLUS, WOS BIOSIS, WOS Core Collection, Proquest Dissertations, Theses Global, PROSPERO, Cochrane Library, and BASE were searched using the keywords “biomarker” and “inner ear”. Of the initially identified 1502 studies, 34 met the inclusion criteria. The identified biomarkers were classified into diagnostic, prognostic, therapeutic, and pathognomonic; many were detected only in the inner ear or temporal bone. The inner-ear-specific biomarkers detected in peripheral blood included otolin-1, prestin, and matrilin-1. Various serum antibodies correlated with inner ear diseases (e.g., anti-type II collagen, antinuclear antibodies, antibodies against cytomegalovirus). Further studies are advised to elucidate the clinical significance and diagnostic or prognostic usage of peripheral biomarkers for inner ear disorders, filling in the literature gaps with biomarkers pertinent to the otology clinical practice and integrating functional and molecular biomarkers. These may be the building blocks toward a well-structured guideline for diagnosing and managing some audio-vestibular disorders.

26 April 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AHAleena Amjad Hafeeez
Aleena Amjad Hafeeez
KBKarina Cavalcanti Bezerra
Karina Cavalcanti Bezerra
ZJZaharadeen Jimoh
Zaharadeen Jimoh
FSFrancesca B Seal
Francesca B Seal
JRJoan Louise Robinson
Joan Louise Robinson
NGNahla A Gomaa
Nahla A Gomaa
There are no narrative or systematic reviews of hearing loss in patients with congenital syphilis. The aim of this study was to perform a scoping review to determine what is known about the incidence, characteristics, prognosis, and therapy of hearing loss in children or adults with presumed congenital syphilis. PROSPERO, OVID Medline, OVID EMBASE, Cochrane Library (CDSR and Central), Proquest Dissertations and Theses Global, and SCOPUS were searched from inception to March 31, 2023. Articles were included if patients with hearing loss were screened for CS, ii) patients with CS were screened for hearing loss, iii) they were case reports or case series that describe the characteristics of hearing loss, or iv) an intervention for hearing loss attributed to CS was studied. Thirty-six articles met the inclusion criteria. Five studies reported an incidence of CS in 0.3% to 8% of children with hearing loss, but all had a high risk of bias. Seven reported that 0 to 19% of children with CS had hearing loss, but the only one with a control group showed comparable rates in cases and controls. There were 18 case reports/ case series (one of which also reported screening children with hearing loss for CS), reporting that the onset of hearing loss was usually first recognized during adolescence or adulthood. The 7 intervention studies were all uncontrolled and published in 1983 or earlier and reported variable results following treatment with penicillin, prednisone, and/or ACTH. The current literature is not informative with regard to the incidence, characteristics, prognosis, and therapy of hearing loss in children or adults with presumed congenital syphilis.

Verified
Journal Article
Open access
PDF file
FTFaith Trinh
Faith Trinh
SJSukhdeep Jatana
Sukhdeep Jatana
HFHaley Danielle Frerichs
Haley Danielle Frerichs
ZJZaharadeen Jimoh
Zaharadeen Jimoh
SMSteffane McLennan
Steffane McLennan
SKShahzeer Karmali
Shahzeer Karmali
Introduction: The role of Collis gastroplasty has traditionally been reserved for patients with a shortened esophagus due to chronic gastroesophageal reflux disease (GERD). However, its necessity has been questioned, leading to a decline in popularity. This systematic review and meta-analysis aimed to evaluate the efficacy of hiatal hernia repair with fundoplication, with versus without Collis gastroplasty. Methods: A systematic search of Ovid MEDLINE, Ovid Embase, Scopus, Web of Science Core Collection, and the Cochrane Library (via Wiley) was performed in May 2025. Studies were included if they compared outcomes or the safety profile of Collis gastroplasty versus no Collis gastroplasty during fundoplication for hiatal hernia repair. Meta-analyses were conducted using a random-effects model and restricted maximum likelihood. Results: Of 664 unique results, 17 studies comprising 4048 patients were included. There was a female predominance (65.4%), with a weighted mean age of 58.9 ± 14.0 years and follow-up of 43.5 ± 43.1 months. Patients who underwent Collis gastroplasty represented 35.8% of the cohort. Nissen fundoplication was the most common procedure in both the Collis (91.9%) and non-Collis (84.5%) groups. Most studies had selection bias, in which only patients who did not have sufficient intraoperative intra-abdominal esophageal length underwent Collis gastroplasty. Recurrence rates were similar (13.5% vs. 13.2%). Collis gastroplasty was not associated with a reduction in hiatal hernia recurrence (OR 0.53, 95% CI 0.23–1.22). Symptom outcomes, including regurgitation (OR 0.53, 95% CI 0.05–5.39), reflux (OR 0.81, 95% CI 0.03–22.12), dysphagia (OR 1.12, 95% CI 0.62–2.04), and use of antireflux medication on follow-up (OR 1.15, 95% CI 0.62–2.15), were not significantly different. However, Collis gastroplasty was associated with a higher risk of complications, including overall complications (OR 2.63, 95% CI 1.55–4.46), leak (OR 3.35, 95% CI 1.11–10.05), and surgical site infection (OR 8.28, 95% CI 1.16–59.10). There were no significant differences in abscess formation (OR 5.97, 95% CI 0.77–46.49), length of stay (mean difference 0.36 days, 95% CI −0.30 to 1.01), readmission (OR 1.13, 95% CI 0.36–3.60), reoperation (OR 1.24, 95% CI 0.64–2.41), or mortality (OR 1.08, 95% CI 0.45–2.57). Conclusions: Collis gastroplasty was not associated with a decreased risk of hiatal hernia recurrence or improvement in other efficacy measures, but this is in the context of a strong component of selection bias. In this context, there may be a role for Collis gastroplasty in difficult cases if the rate of recurrence does not differ from those with sufficient length, but this must be balanced against a significantly increased risk of complications.

23 July 2025 in Foregut: The Journal of the American Foregut Society
Verified
Journal Article
Closed access
DLDavy Lau
Davy Lau
SJSukhdeep Jatana
Sukhdeep Jatana
MEMayan ElSayed
Mayan ElSayed
ZJZaharadeen Jimoh
Zaharadeen Jimoh
JKJanice Kung
Janice Kung
STSimon R. Turner
Simon R. Turner
Introduction: Esophageal cancer often presents at a late stage. Along with tumor metabolic burden, dysphagia can lead to malnutrition and worsen outcomes in esophageal cancer. Various nutrition modalities have been trialed for patients undergoing neoadjuvant therapy prior to esophagectomy but there is a lack of consensus as to which strategy is optimal. Methods: A systematic review of Ovid MEDLINE, Ovid Embase, Scopus, Web of Science Core Collection, and Cochrane Library was performed. Studies were included that examined esophageal cancer patients undergoing neoadjuvant therapy, assessing preoperative nutritional strategies including nasoenteric feeds, percutaneous (PEG) or surgical gastrostomy (G-tube) or jejunostomy tubes (J-tube), and esophageal stents. Risk of bias was assessed using the MINORS tool. Results: Of 3393 retrieved records, 23 were included. Nutritional strategies studied included stents (n = 16), J-tube (n = 8), G-tube (n = 3), nasogastric tube (NG, n = 2), and PEG (n = 2). Most feeding strategies showed mixed results regarding improvement, stability or decrease in weight or albumin during neoadjuvant therapy. Complications appeared most severe for endoscopic or surgical tubes (obstruction, migration) and stents (perforation, migration, intolerance), which occasionally required operation. Conclusion: There is significant heterogeneity in the literature on whether preoperative feeding modalities are associated with improved nutritional outcomes in this population. At the same time, endoscopic or surgical feeding tubes and esophageal stents are clearly associated with higher risk complications. Future studies standardizing study designs, done in a prospective comparative fashion may be beneficial, along with identification of patients who would benefit most.